Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Richard B S Roden"'
Autor:
Ravi K Anchoori, Ssu-Hsueh Tseng, Hua-Ling Tsai, Vikrant Palande, Michelle A Rudek, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0305710 (2024)
There is an urgent unmet need for more targeted and effective treatments for advanced epithelial ovarian cancer (EOC). The emergence of drug resistance is a particular challenge, but small molecule covalent inhibitors have promise for difficult targe
Externí odkaz:
https://doaj.org/article/2db63bf16e0e4c7bacaecfd447382c57
Autor:
Ravi K Anchoori, Vidyasagar Anchoori, Brandon Lam, Ssu-Hsueh Tseng, Samarjit Das, Fernanda Carrizo Velasquez, Balasubramanyam Karanam, Deepika Poddatoori, Ramesh Patnam, Michelle A Rudek, Yung-Nien Chang, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 18, Iss 6, p e0285221 (2023)
Bortezomib has been successful for treatment of multiple myeloma, but not against solid tumors, and toxicities of neuropathy, thrombocytopenia and the emergence of resistance have triggered efforts to find alternative proteasome inhibitors. Bis-benzy
Externí odkaz:
https://doaj.org/article/9b4e3a1ede114e78983838d19f4e8731
Autor:
Ravi K Anchoori, Logan George, Ssu-Hsueh Tseng, Brandon Lam, Srinidhi Polkampally, Anjali D Amiano, Palmer Foran, Hannah Tsingine, Harideep Samanapally, Fernanda Carrizo Velasquez, Samarjit Das, Deyin Xing, Ahmad Bin Salam, Balasubramanyam Karanam, Chien-Fu Hung, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0256937 (2021)
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-p
Externí odkaz:
https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d
Autor:
Ravi K Anchoori, Marietta Tan, Ssu-Hsueh Tseng, Shiwen Peng, Ruey-Shyang Soong, Aliyah Algethami, Palmer Foran, Samarjit Das, Chenguang Wang, Tian-Li Wang, Hong Liang, Chien-Fu Hung, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0227727 (2020)
We sought to design ubiquitin-proteasome system inhibitors active against solid cancers by targeting ubiquitin receptor RPN13 within the proteasome's 19S regulatory particle. The prototypic bis-benzylidine piperidone-based inhibitor RA190 is a michae
Externí odkaz:
https://doaj.org/article/d0a6399b2dc8409e97710fa3b4fd75f6
Publikováno v:
PLoS Pathogens, Vol 12, Iss 5, p e1005587 (2016)
Externí odkaz:
https://doaj.org/article/27b1d46accc540128b7f6c06d425b098
Publikováno v:
PLoS Pathogens, Vol 11, Iss 10, p e1005243 (2015)
Persistent papillomas developed in ~10% of out-bred immune-competent SKH-1 mice following MusPV1 challenge of their tail, and in a similar fraction the papillomas were transient, suggesting potential as a model. However, papillomas only occurred in B
Externí odkaz:
https://doaj.org/article/3c4d46f5769b4fa5af3a84fae7c5cba9
Autor:
Shiwen Peng, Joshua W Wang, Balasubramanyam Karanam, Chenguang Wang, Warner K Huh, Ronald D Alvarez, Sara I Pai, Chien-fu Hung, T-C Wu, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e116389 (2015)
Clinical studies suggest that responses to HPV16 E6E7L2 fusion protein (TA-CIN) vaccination alone are modest, and GPI-0100 is a well-tolerated, potent adjuvant. Here we sought to optimize both the immunogenicity of TA-CIN via formulation with GPI-010
Externí odkaz:
https://doaj.org/article/eb5de519610f4693a11d4aece4c3c34b
Autor:
Joshua W Wang, Subhashini Jagu, Chenguang Wang, Henry C Kitchener, Sai Daayana, Peter L Stern, Susana Pang, Patricia M Day, Warner K Huh, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101576 (2014)
Antibodies specific for neutralizing epitopes in either Human papillomavirus (HPV) capsid protein L1 or L2 can mediate protection from viral challenge and thus their accurate and sensitive measurement at high throughput is likely informative for moni
Externí odkaz:
https://doaj.org/article/ccaad3a7b3c7411eb22353b9a75fde34
Autor:
Kihyuck Kwak, Rosie Jiang, Joshua W Wang, Subhashini Jagu, Reinhard Kirnbauer, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97232 (2014)
The licensed human papillomavirus (HPV) vaccines elicit type-restricted immunity but do not target cutaneous HPV types of the beta genus that are associated with non-melanoma skin cancer in immune-compromised patients, and it is unclear if these dive
Externí odkaz:
https://doaj.org/article/ffb8d47ca9c849cc801029a765f26bd2
Autor:
Subhashini Jagu, Kihyuck Kwak, Balasubramanyam Karanam, Warner K Huh, Vijayarangam Damotharan, Sudha V Chivukula, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e55538 (2013)
We sought to define the protective epitopes within the amino terminus of human papillomavirus (HPV) type 16 minor capsid protein L2. Passive transfer of mice with rabbit antisera to HPV16 L2 peptides 17-36, 32-51 and 65-81 provided significant protec
Externí odkaz:
https://doaj.org/article/57ab5682135c4e5f828a9c3ed2349da5